Phase 3 Randomized Study of Loncastuximab Tesirine plus Rituximab versus Immunochemotherapy in Patients with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) – LOTIS-5

Email this document.

Enter your email address below to send this document.

PLACEHOLDER START

[ninja_form id=1]

Important Notice

in footer